Krystal Biotech, Inc. Board of Directors

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Mr. Krish S. Krishnan M.B.A., M.S.

Mr. Krish S. Krishnan M.B.A., M.S.

Founder, Chairman, President & CEO

Mr. David Chien

Mr. David Chien

Senior Vice President of Clinical Development

Dr. Stephane Paquette Ph.D.

Dr. Stephane Paquette Ph.D.

Vice President of Corporate Development

Ms. Christine Wilson

Ms. Christine Wilson

Head of U.S. Sales & Marketing

Mr. Josh Suskin

Mr. Josh Suskin

Director of Human Resources & Operations

Ms. Suma M. Krishnan

Ms. Suma M. Krishnan

Founder, President of R&D and Director

Mr. Laurent Goux

Mr. Laurent Goux

Senior VP & GM of Europe

Mr. John Thomas

Mr. John Thomas

General Counsel & Corporate Secretary

Mr. John Karakkal

Mr. John Karakkal

Vice President of North American Sales & Marketing

Ms. Kathryn A. Romano CPA

Ms. Kathryn A. Romano CPA

Executive VP & Chief Accounting Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.